CN113133974B - Muskmelon seed powder suspension granule as well as preparation method and application thereof - Google Patents
Muskmelon seed powder suspension granule as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN113133974B CN113133974B CN202110442614.5A CN202110442614A CN113133974B CN 113133974 B CN113133974 B CN 113133974B CN 202110442614 A CN202110442614 A CN 202110442614A CN 113133974 B CN113133974 B CN 113133974B
- Authority
- CN
- China
- Prior art keywords
- parts
- seed powder
- powder suspension
- muskmelon
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a muskmelon seed powder suspension granule and a preparation method and application thereof, wherein the muskmelon seed powder suspension granule comprises 40 parts of muskmelon seed powder and 60 parts of auxiliary materials in parts by weight, and the auxiliary materials comprise 40 parts of xylitol, 12.4 parts of hydroxypropyl methylcellulose, 5 parts of sodium carboxymethylcellulose and 2.6 parts of superfine silica gel powder in parts by weight. The muskmelon seed powder suspension granule can fully utilize muskmelon seeds, the development and utilization degree of the muskmelon seeds are improved, the prepared suspension granule can be used for treating liver diseases, compared with an oral preparation and an injection, the prepared suspension granule is good in safety and few in adverse reaction, and the results of a hard light experiment and a high humidity experiment show that the muskmelon seed powder suspension granule has good stability, is convenient for a patient to take and carry, and is good in taste and strong in patient compliance.
Description
Technical Field
The invention belongs to the technical field of medicine preparation, and particularly relates to a muskmelon seed powder suspension granule as well as a preparation method and application thereof.
Background
China is the biggest melon producing country in the world and accounts for more than 40% of the total yield and the total area of the world. According to the data 2015 published by the national statistical bureau, the total melon yield in China reaches 1527.07 ten thousand tons, and the melon seeds generally account for 2-15% of the mass of a single melon. Therefore, about 30.54 to 229.06 million tons of melon seeds can be produced every year, and most of the melon seeds are not utilized and discarded except a small amount of melon seeds are reserved for breeding, so that great waste is caused. Therefore, the development of the melon seed powder suspension particles is also effective in resource utilization and has strong practical significance.
The muskmelon has a long history of medicinal use, and is recorded in the writings of the Chinese materia Medica, the park of medicine, the medical dictionary, the white palace and the book of Baodiei medicine. In the first part of the "chinese pharmacopoeia" 2015 edition: the muskmelon seed has the functions of clearing away lung-heat, moistening the intestines, dissolving stasis, expelling pus, treating injuries and relieving pain, treating cough due to lung heat, constipation, pulmonary abscess, traumatic injury, fracture of bones and muscles and the like, and has obvious treatment effects of preventing osteoporosis, relieving pain and resisting inflammation and the like. The semen melo extract is prepared from mature dry seed of Cucumis melo of Cucurbitaceae by special process, and has effects of reducing permeability of local capillary vessel of fracture, reducing inflammatory exudation, and promoting recovery of local blood circulation disorder; the whole blood viscosity and the erythrocyte aggregation degree can be reduced, the local blood circulation of the callus can be improved, and a good blood supply environment is provided for osteocytes; can also inhibit release of prostaglandin, and can relieve pain. In the process of promoting the early healing of fracture, the muskmelon seed extract and the supplemented osteoinductive polypeptide biological factor have synergistic effect, thereby promoting the synthesis of the bone-derived growth factor.
The suspension granule has the advantages of stable quality, convenient transportation, carrying and oral administration, and can improve the bioavailability of insoluble drugs in vivo. Meanwhile, the buccal tablet has the characteristics of good taste, convenient taking and the like, is particularly suitable for children, the old and patients with dysphagia, and increases the compliance of taking medicines.
At present, muskmelon seeds are mostly used for preparing compound preparations such as cervus and cucumis polypeptide injection, and the prior art discloses a preparation process method of the cervus and cucumis polypeptide injection. The research on the oral preparation of cervus and cucumis polypeptide in recent years in China is relatively lacked, and only in the prior art, effective products are respectively extracted from the deer bone and the melon seeds and then mixed, impurity protein is removed by using a method for adjusting the pH value in the extraction process, and the oral liquid preparation with single dose is prepared.
Through repeated experiments, researchers of the invention explore a muskmelon seed powder suspension granule and a preparation method thereof, which can comprehensively improve the safety, stability, effectiveness and compliance of the preparation and can be used for treating liver diseases.
Disclosure of Invention
In order to solve the problems, the invention provides a muskmelon seed powder suspension granule and a preparation method and application thereof through multiple creative researches, wherein muskmelon seed powder is taken as a raw material, appropriate auxiliary materials are added to prepare the muskmelon seed powder suspension granule, and a prescription with good formability is determined by taking the appearance, filling property and fluidity of the granule as investigation indexes of the suspension granule, so that the muskmelon seed powder suspension granule has the characteristics of good stability, good taste, effectiveness, safety, convenience in taking, high bioavailability and the like.
The invention solves the technical problem by adopting the following technical scheme that the muskmelon seed powder suspension particles comprise 40 parts of muskmelon seed powder and 60 parts of auxiliary materials in parts by weight, wherein the auxiliary materials comprise 40 parts of xylitol, 12.4 parts of hydroxypropyl methylcellulose, 5 parts of sodium carboxymethylcellulose and 2.6 parts of superfine silica gel powder in parts by weight.
Further, the melon seed powder suspension particles are prepared according to the following method: the preparation method comprises the steps of uniformly mixing 40 parts by weight of melon seed powder and 60 parts by weight of auxiliary materials, firstly spraying a wetting agent on the mixed material to wet the mixed material, then uniformly spraying an adhesive on the wetted material to prepare a soft material, sieving the obtained soft material with a 16-mesh sieve to prepare wet granules, drying the wet granules, sieving with a 12-mesh sieve to complete granules, and finally sieving with a 80-mesh sieve to remove fine powder to obtain the melon seed powder suspension granules.
Further, the wetting agent is 80% by mass of ethanol. The usage amount of ethanol is 5-10ml based on 100g of the mixed material.
Further, the adhesive is PVP-K30 solution with the mass fraction of 5%. The PVP-K30 solution was used in an amount of 20ml based on 100g of the mixture.
Further, the drying is carried out in an air-blast drying oven at 50-60 ℃.
The muskmelon seed powder suspension granule can be used for treating liver diseases, such as liver injury, especially acute liver injury.
Compared with the prior art, the invention has the following advantages:
the muskmelon seed powder suspension granule is prepared into the suspension granule, and the prescription with good formability is determined by taking the appearance, filling property and fluidity of the granule as the investigation indexes of the suspension granule, so that the muskmelon seed powder suspension granule has the characteristics of good stability, good taste, effectiveness, safety, convenience in taking, high bioavailability and the like. The muskmelon seed powder suspension granules can be used for treating liver diseases, and experiments prove that the muskmelon seed powder suspension granules have quick, safe and effective effect on liver injury. Compared with an oral preparation and an injection, the obtained suspension granule has the advantages of good safety, less adverse reaction, good stability as shown by results of a strong light experiment and a high humidity experiment, convenience for oral administration and carrying of a patient, good taste and strong patient compliance.
Drawings
Fig. 1 is a graph showing the relationship between the amounts (abscissa) and desired values (ordinate) of lactose (a), hypromellose (B), and sodium carboxymethylcellulose (C) as three excipients.
FIG. 2 is the change in mouse liver index in acute liver injury; wherein the content of the first and second substances, ** P<0.01, vs Normal group; # P<0.05, vs model set.
FIG. 3 shows the variation of the muskmelon seed powder suspension granules on ALT and AST in the serum of mice with acute liver injury; wherein the content of the first and second substances, *** P<0.01, vs Normal group; ## P<0.01, vs model set.
Figure 4 is H & E staining (× 200) of representative liver tissues in mice (n = 3).
Detailed Description
In order to further illustrate the technical means and technical effects adopted by the invention, the muskmelon seed powder suspension granules, and the preparation method and application thereof are described in detail in the following with reference to specific examples.
The muskmelon seed powder suspension granule comprises the following raw materials in parts by weight: 40 parts of melon seed powder and 60 parts of auxiliary materials. The preparation process comprises the following steps: uniformly mixing 40 parts of melon seed powder and 60 parts of auxiliary materials, and spraying a proper amount of wetting agent on the mixed material to wet the mixed material, wherein the wetting agent is 80% ethanol in mass fraction; then evenly spraying a proper amount of adhesive on the wetted mixed material to prepare a soft material, wherein the adhesive is preferably PVP-K30 solution with the mass fraction of 5%. And (3) sieving the soft material with a 16-mesh sieve to prepare wet granules, then putting the wet granules into a forced air drying oven at 50-60 ℃ for drying, sieving the dry granules with a 12-mesh sieve for finishing, and finally sieving with a 80-mesh sieve to remove fine powder to obtain the muskmelon seed powder suspension granules.
The usage amount of the wetting agent ethanol is 5-10ml, preferably 7.5ml calculated by 100g of the mixed material; the amount of the PVP-K30 solution used as a binder was 20ml.
The muskmelon seed powder is obtained by crushing muskmelon seeds and then sieving the crushed muskmelon seeds with a 100-mesh sieve.
The adjuvants of the suspension granule comprise diluent agent, suspending agent, adhesive, and lubricant, and the adjuvants are optimized below.
(1) Screening of diluents
The diluent of the suspension granule needs to select water-soluble auxiliary materials, so that the granule can be rapidly dispersed and dissolved in water.
The water-soluble diluents are: lactose, xylitol, mannitol and the like, the drug loading of a suspension granule prescription is set to be 40%, a single-factor experiment is designed to screen a proper diluent, and the experiment design formula is shown in table 1:
TABLE 1 Diluent screening protocol
Suspension granules were prepared according to the three formulations of table 1 and the above preparation method, and the three formulations produced granules with little difference in flowability and filling property but with xylitol having a better taste, so xylitol was selected as the diluent.
(2) Screening adhesive
The muskmelon seeds belong to seed medicinal materials, and the seeds generally contain more oily hydrophobic components and mineral substances, so the viscosity is poor, and the granulation process not only needs to prepare a liquid adhesive to bond materials, but also needs to add a dry adhesive internally to enhance the bonding force among particles.
Selecting a cellulose derivative with stronger viscosity and povidone K30 to carry out a single-factor experiment to screen a proper dry adhesive, setting the drug-loading rate of a suspension granule prescription to be 40%, wherein the experiment design formula is shown in table 2:
TABLE 2 Binder screening protocol
And determining the type of the adhesive by taking the appearance of the particles and the state of the particles dissolved in water as investigation indexes. The results for suspension granules prepared from formulations # 1 and # 2 show that: the granules taking sodium carboxymethylcellulose as an internal adhesive have better granular state, better dispersion effect after being dissolved in water and longer suspension time.
(3) D-optimal mixing design optimization prescription
The primary selection prescription is determined through single-factor experiments, but the optimal proportion of each auxiliary material in the prescription needs to be further optimized. The invention adopts Design-Expert 8.0.6 software to carry out D-optimal mixing Design, and optimizes the prescription of the muskmelon seed powder suspension particles. The specific process is to respectively evaluate the fluidity and the filling property of the granules by taking the compression degree and the bulk density as indexes, and because the drug-loading rate of the prescription is 40 percent, the xylitol, the hydroxypropyl methylcellulose, the sodium carboxymethylcellulose and the micro-powder silica gel together account for 60 percent of the prescription, and the dosage range is shown in the following table 3:
TABLE 3 dosage ranges of adjuvants
Selecting a D-optimal mixing design to obtain an experimental schedule, preparing suspension particles of each group of formulas as shown in the following table 4, measuring the compressibility and bulk density of the suspension particles of each group of formulas, and inputting results to perform mathematical model fitting analysis.
TABLE 4 Experimental arrangement chart
The mathematical model fitting equation obtained is given by the following formula:
compression ratio =26.00 × A +5.01 × B +26.34 × C +36.74 × D +33.12 × A × B-7.96 × A × D +39.09 × B × C +4.92 × B × D +254.09 × B × C × (B-C) +170.08 × A × B × D ^2
Bulk density =0.25 × A +0.24 × B +0.28 × C +0.31 × D +0.033 × A × C +0.021 × A × D +0.037 × B × C +0.071 × C × D +0.64 × B × C × (B-C) -2.04 × A × C ^2 × D +0.10 × A × D ^2 (A-D) ^2+5.46 × B × C × (B-C) ^2
The obtained mathematical model is subjected to regression analysis, as shown in table 5, the models selected by 2 indexes all reach a significance level with P <0.05, the closer the judgment coefficient and the corrected judgment coefficient are to 1, the better the correlation between the predicted value and the measured value of the model is, and the judgment coefficients of 2 equations are 0.9217 and 0.9926 respectively, which shows that the equation fitting degree of the 2 indexes is better. The two indexes have strong correlation with the change of the dosage of each auxiliary material in the prescription, and the obtained regression equation can be used for more accurately predicting to obtain the optimal prescription.
TABLE 5 regression analysis of the indices
Table 5 shows that the models all reached a significant level of P < 0.05.
(4) Optimal prescription and outcome verification
According to a regression equation, the optimal function (Optimization) of Design-Expert 8.0.6 experimental Design software is applied, the variation range of each component is set firstly, then the limiting conditions of each index are set to determine a target response value, and after the software runs, the prediction is carried out from random combination until the target response value is reached or approached. The prescription was optimized using the compressibility and bulk density as indices to obtain 7 sets of adjuvant ratios and predicted values for each index, as shown in table 6.
Table 6.7 group auxiliary material proportion and optimization result of each index
The optimal (highest expected value) group 1 in table 6 is selected, and the optimal adjuvant formula ratio is: xylitol, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, aerosil: 40.0 percent to 12.4 percent to 5.0 percent to 2.6 percent, and the suspension granules comprise 40 parts of melon seed powder and 60 parts of auxiliary materials based on 100 parts of raw materials, wherein the auxiliary materials comprise: 40 parts of xylitol, 12.4 parts of hydroxypropyl methylcellulose, 5 parts of sodium carboxymethylcellulose and 2.6 parts of superfine silica gel powder.
3 verification experiments were performed according to the optimal adjuvant formulation, and the results are shown in Table 7. As can be seen from table 7, the deviations between the compression CI and the bulk density are less than 10%, which indicates that the fitting equation obtained by the experiment can better describe the relationship between the factors and the indexes (note: deviation = (predicted value-measured value)/predicted value × 100%).
TABLE 7 verification of the results of the experiments
| Index (I) | 1 | 2 | 3 | Measured average value | Prediction value | Deviation of |
| Degree of compression CI | 25.60 | 27.55 | 27.05 | 26.73 | 26.12 | -2.33％ |
| Bulk density/g.cm -3 | 0.3008 | 0.3009 | 0.3002 | 0.3006 | 0.3021 | 0.50％ |
The first set of recipes were then optimized, with the results shown in FIG. 1. The expected value of the optimal auxiliary material prescription is 0.828, the expected value represents the result of multi-index synchronous optimization, the closer the value is to 1, the better the value is, and the closer to 1, the more the optimized prescription proportion can simultaneously meet the limiting conditions of each index.
Stability test
(1) Experiment with intense light irradiation
9 samples (hereinafter referred to as "test samples") of the suspension granules to be tested were prepared according to the formulation of the suspension granules, 3g of each sample was placed in 9 beakers, the beakers were placed in a drug stability test box and placed under the condition of an illumination intensity of 4500lx ± 500lx for 10 days, 9 samples were taken out on the 5 th and 10 th days, respectively, weighed, the properties of the granules and the change in PH were examined, and the results were averaged as shown in table 8.
(2) High humidity experiment
Weighing 6 test suspension particle samples (hereinafter referred to as "samples"), wherein each sample is about 3g, placing the samples into a weighing bottle, placing the weighing bottle into a constant humidity closed container, placing the weighing bottle for 10 days under the conditions of 25 ℃ and 75 +/-5% of relative humidity (the conditions of constant humidity are realized by selecting saturated sodium chloride solution), completely taking out the 6 samples on the 5 th day and the 10 th day respectively, weighing, inspecting the moisture absorption weight increment, properties and PH value conditions, and taking an average value, wherein the results are shown in table 8.
TABLE 8 results of the high light irradiation test and the high humidity test
| | Day | 0 | 5 days | 10 days |
| Experiment of pH with intense light irradiation | 10.15 | 11.15 | 10.03 | |
| High humidity Experimental pH | 10.15 | 9.42 | 9.15 | |
| Moisture absorption weight gain in high humidity experiments | 3.1439g | 3.1445g | 3.1455g | |
| Moisture |
0 | 0.0191％ | 0.0509％ |
Table 8 shows that in the influence factor experiment, the pH value of the obtained melon seed powder suspension particles fluctuates in the strong light irradiation experiment, the pH value is in a decreasing trend in the high humidity experiment, and the moisture absorption weight gain is not more than 0.1%, which indicates that the stability of the obtained melon seed powder suspension particles is good.
Taste of food
The muskmelon seed powder suspension particles obtained by the invention are light yellow particles, are light in smell and sweet in taste, have good mouthfeel, can be accepted by most people, and have strong patient compliance.
Experiment of the obtained semen melo powder suspension granule for treating liver diseases
(1) Materials:
experimental animals: c57BL/6 male mice, body weight (25 ± 3) g, mice purchased from experimental animals center in south of heonan, experimental animals production license: SCXK 2017-0001. The animals are bred in an animal house of a first subsidiary hospital of the university of science and technology in Henan, the temperature is 18-25 ℃, the relative humidity is 40-70%, and the illumination is carried out for 12 hours in a day-and-night cycle.
Experimental reagent: CCl 4 And olive oil, CCl 4 The manufacturer is national drug group chemical reagent limited, and the olive oil manufacturer is Spanish Ebeck limited.
An experimental instrument: nikon Eclipse E100 electron microscope, hitachi full-automatic biochemical analyzer.
(2) Experimental methods
Establishing a model: the male C57BL/6 mouse is taken as a research object, the establishment of a mouse acute liver injury model refers to The carbon tetrachloride model in The document reported by Scholten D et al, and The acute liver injury model is subjected to single intraperitoneal injection of a mediumCCl in an amount fraction of 0.5% 4 The injection amount of the olive oil mixed solution per mouse is 10uL g -1 Injecting 10uL CCl with the mass fraction of 0.5 percent according to the weight of each gram of the mouse 4 The olive oil mixture was injected intraperitoneally and the mice were sacrificed 24h before collecting specimens. 0.5% CCl 4 The olive oil mixture is CCl 4 Olive oil as a solvent, CCl 4 The mass fraction in olive oil is 0.5%.
Animal grouping and administration method: animals were divided into normal group (n = 7), model group (n = 7), melon seed powder suspended particle group (n = 7). Acute liver injury experiment: administering the semen melo powder suspension granule medicine (equivalent to injecting CCl into the semen melo powder suspension granule group) 36h before molding and every 12h after intragastric administration 4 The administration is carried out three times before the olive oil is added), the melon seed powder suspension granule medicine is prepared by dissolving the melon seed powder suspension granule in physiological saline for clinical use, and the concentration of the melon seed powder suspension granule in the physiological saline is 500 mg/ml -1 . The dose per mouse was 0.2 uL.g -1 I.e. 0.2uL per gram body weight of mice. Normal and model groups were only in the order of 0.2 uL.g -1 The corresponding volume of solvent (physiological saline) was administered. After the last administration for 10min, the muskmelon seed powder suspension granule group is administered at a dose of 10uL g in the abdominal cavity of a mouse -1 CCl with injection mass fraction of 0.5% 4 Olive oil mixture, samples were collected at 24h post-molding sacrifice and fasted for 12 hours prior to sacrifice. After the last time of the model group, the physiological saline is given for 10min, and then the 10 uL.g of the physiological saline is added into the abdominal cavity of the mouse -1 CCl with injection mass fraction of 0.5% 4 Olive oil mixture, samples were sacrificed 24h after molding and fasted for 12 hours before sacrifice.
Collecting a specimen: after the mice were anesthetized with inhaled sevoflurane, the capillary orbit was bled and sacrificed. The livers were dissected and collected, rinsed with normal saline, wiped, weighed, fixed with 4% paraformaldehyde, and liver index (%) = liver weight/body weight 100.
ALT and AST assay: standing the whole blood at room temperature for 2h, centrifuging at low temperature for 15min, collecting the upper serum, and detecting ALT and ALT activity in the serum by using a full-automatic biochemical analyzer. Wherein the centrifugal force of the centrifuge was 2000g.
Liver tissue section staining: after the liver tissue is fixed by 10% formaldehyde for 24H, the liver tissue is dehydrated conventionally and embedded by paraffin, and H & E staining is carried out to evaluate the pathological damage degree.
(3) Results of the experiment
The influence of the muskmelon seed powder suspension granules on the liver index of mice with acute liver injury is as follows:
compared with the normal group, the liver index of the model group mice is obviously increased (P < 0.01), which indicates that the liver index of the mice in acute liver injury is increased. Compared with the model group, the liver index of the mice is obviously reduced after the administration of the muskmelon seed powder suspension granules (P < 0.05), and the fact that the muskmelon seed powder suspension granules can improve the increase of the liver index in acute liver injury is suggested, as shown in fig. 2.
Compared with the normal group, the serum ALT and AST activities of the model group mice are obviously increased (P)<0.001 Compared with the model group, the mice with the muskmelon seed powder suspension granule group have obviously reduced serum ALT and AST activities (P)<0.01 Showing that the muskmelon seed powder suspension particles of the invention are in CCl 4 The increased ALT and AST activity of mice caused by the muskmelon seed powder suspension particles has a reducing effect, but compared with a normal group, the serum ALT and AST activity of mice in the muskmelon seed powder suspension particle group is obviously increased (P)<0.001 The muskmelon seed powder suspension granules can improve the elevation of the serum ALT and AST activities of mice with acute liver injury, but can not reverse the activities. As shown in fig. 3 (a) and 3 (B).
HE staining: as shown in FIG. 4, the normal group of mice had intact hepatocyte structures, regular arrangement and clear hepatic lobule structures. In the model group, a large number of cells around the vascular zone and the portal vein of the mouse have vacuole-like necrosis, inflammatory infiltration, disordered arrangement and incomplete hepatic lobule structure, and a typical acute poisoning phenomenon appears. The muskmelon seed powder suspension particles can improve the inflammatory lesion and the necrosis degree of the liver cells of the mice.
The experiments prove that: the muskmelon seed powder suspension granule can improve acute liver injury and treat CCl 4 Has obvious curative effect on induced acute liver injuryAnd (5) fruit.
The above description is only an embodiment of the present invention, and is not intended to limit the present invention in any way, and the present invention may also have other embodiments according to the above structures and functions, and is not listed again. Therefore, any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention by those skilled in the art can be made within the technical scope of the present invention.
Claims (4)
1. The muskmelon seed powder suspension particles for treating and improving liver injury are characterized by comprising 40 parts of muskmelon seed powder and 60 parts of auxiliary materials in parts by weight, wherein the auxiliary materials comprise 40 parts of xylitol, 12.4 parts of hydroxypropyl methylcellulose, 5 parts of sodium carboxymethylcellulose and 2.6 parts of superfine silica gel powder in parts by weight;
the melon seed powder suspension particles are prepared by the following method: the preparation method comprises the steps of uniformly mixing 40 parts of melon seed powder and 60 parts of auxiliary materials in parts by weight, firstly spraying 80% mass percent of ethanol on the mixed material to moisten the mixed material, then uniformly spraying 5% mass percent of PVP-K30 solution on the moistened material to prepare a soft material, sieving the obtained soft material with a 16-mesh sieve to prepare wet particles, drying the wet particles, sieving with a 12-mesh sieve to complete the particles, and finally sieving with an 80-mesh sieve to remove fine powder to obtain the melon seed powder suspension particles.
2. A melon seed powder suspension granulate for use in the treatment and amelioration of liver damage as claimed in claim 1, characterised in that the amount of ethanol used is 5-10ml.
3. A melon seed powder suspension granule for use in the treatment and amelioration of liver damage as claimed in claim 1, wherein the PVP-K30 solution is used in an amount of 20ml.
4. A melon seed powder suspension granule for use in the treatment and amelioration of liver damage as claimed in claim 1, wherein the drying is a forced air drying oven drying at 50-60 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110442614.5A CN113133974B (en) | 2021-04-23 | 2021-04-23 | Muskmelon seed powder suspension granule as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110442614.5A CN113133974B (en) | 2021-04-23 | 2021-04-23 | Muskmelon seed powder suspension granule as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113133974A CN113133974A (en) | 2021-07-20 |
| CN113133974B true CN113133974B (en) | 2023-01-31 |
Family
ID=76812185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110442614.5A Active CN113133974B (en) | 2021-04-23 | 2021-04-23 | Muskmelon seed powder suspension granule as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113133974B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520856A (en) * | 2003-04-16 | 2004-08-18 | 杨世杰 | Use of muskmelon plant extract in pharmacy |
| WO2008071968A1 (en) * | 2006-12-15 | 2008-06-19 | Ultra Biotech Limited | Cucurbitacin b and uses thereof |
| CN102441023A (en) * | 2011-12-08 | 2012-05-09 | 赵联华 | Injection composition for treating orthopedic diseases |
| CN103040910A (en) * | 2012-12-17 | 2013-04-17 | 海南百思特医药科技有限公司 | Cervus and cucumis polypeptide liposome injection |
| CN103536655A (en) * | 2012-07-11 | 2014-01-29 | 陕西盘龙药业集团股份有限公司 | Osteosynthesis medicine for department of traumatology and preparation method of osteosynthesis medicine |
| CN105519900A (en) * | 2014-10-27 | 2016-04-27 | 哈尔滨天一生态农副产品有限公司 | Field sowthistle herb asthma relieving granules and preparation method thereof |
| KR20190014220A (en) * | 2017-07-28 | 2019-02-12 | 주식회사 동해바이오 | Composition of mixed ferment extraction liquid for hangover elimination and hangover eliminator containing composition as effective ingredient thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015131245A1 (en) * | 2014-03-03 | 2015-09-11 | La Trobe University | Sepsis treatment |
-
2021
- 2021-04-23 CN CN202110442614.5A patent/CN113133974B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520856A (en) * | 2003-04-16 | 2004-08-18 | 杨世杰 | Use of muskmelon plant extract in pharmacy |
| WO2008071968A1 (en) * | 2006-12-15 | 2008-06-19 | Ultra Biotech Limited | Cucurbitacin b and uses thereof |
| CN102441023A (en) * | 2011-12-08 | 2012-05-09 | 赵联华 | Injection composition for treating orthopedic diseases |
| CN103536655A (en) * | 2012-07-11 | 2014-01-29 | 陕西盘龙药业集团股份有限公司 | Osteosynthesis medicine for department of traumatology and preparation method of osteosynthesis medicine |
| CN103040910A (en) * | 2012-12-17 | 2013-04-17 | 海南百思特医药科技有限公司 | Cervus and cucumis polypeptide liposome injection |
| CN105519900A (en) * | 2014-10-27 | 2016-04-27 | 哈尔滨天一生态农副产品有限公司 | Field sowthistle herb asthma relieving granules and preparation method thereof |
| KR20190014220A (en) * | 2017-07-28 | 2019-02-12 | 주식회사 동해바이오 | Composition of mixed ferment extraction liquid for hangover elimination and hangover eliminator containing composition as effective ingredient thereof |
Non-Patent Citations (2)
| Title |
|---|
| Effects of 20 Selected Fruits on Ethanol Metabolism: Potential Health Benefits and Harmful Impacts;Zhang et al.;《Int.J.Environ.Res.Public Health》;20161231;第13卷;第399页 * |
| 甜瓜的营养价值;《吉林蔬菜》;20111215(第06期);第78页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113133974A (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540833A (en) | Broad money sensation total flavonoid capsule, its production method and its application | |
| CN102145106B (en) | Chinese medical composition for treating osteoporosis and granular formulation capable of tonifying kidney and invigorating blood circulation | |
| CN103690782B (en) | A kind of Chinese medicine composition, preparation method and quality determining method for the treatment of climacteric syndrome | |
| CN1757400A (en) | Traditional Chinese medicine granule, and its prepn. method | |
| CN1850161A (en) | Medicine composition for treating pain and preparing method therefor | |
| CN113133974B (en) | Muskmelon seed powder suspension granule as well as preparation method and application thereof | |
| CN1164264C (en) | Dispersed general arasaponin tablet and its prepn and application | |
| CN104940781A (en) | Traditional Tibetan medicine composition for treating nervous system diseases and preparation method thereof | |
| CN101085295A (en) | Freeze dried injection containing muskone and preparation method thereof | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN102240320B (en) | Motherwort and astragalus capsule used for treating prostatic hyperplasia | |
| CN105343260B (en) | The drug for treating chronic ulcerative colitis | |
| CN1586612A (en) | Process for preparing granular powder for treating blood stasis disease and quality control method | |
| CN1704113A (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN1294948C (en) | Medicine for boosting qi, strengthening spleen and nourishing liver and kidney and its preparation method | |
| CN104248678B (en) | Traditional Chinese medicinal extract composition for bone fractures and preparation method and application of extract composition | |
| CN1857632A (en) | Osteoporosis treating compound Chinese preparation and its preparing process | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN107137443A (en) | A kind of composition for relieving fatigue, preparation method and applications | |
| CN114869956B (en) | Pharmaceutical composition for treating post-stroke dyskinesia, and preparation method and application thereof | |
| CN1895346A (en) | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method | |
| CN108567753A (en) | All beam dripping pill and its preparation process | |
| CN1785416A (en) | Medicinal preparation for freating chololithiasis and its preparation method | |
| CN1232274C (en) | Composite medicine for prevention and cure of osteoporosis and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |